

Agonist-evoked calcium entry in vascular smooth muscle cells requires IP₃ receptor-mediated activation of TRPC1

Khalid Tai^a, Marie-Christine Hamaide^b, Huguette Debaix^c, Philippe Gailly^a,
Maurice Wibo^b, Nicole Morel^{a,*}

^a Unit of Cellular Physiology, Université Catholique de Louvain, Bruxelles, Belgium

^b Unit of Experimental Pharmacology, Université Catholique de Louvain, Bruxelles, Belgium

^c Division of Nephrology, Université Catholique de Louvain, Bruxelles, Belgium

Received 21 August 2007; received in revised form 17 December 2007; accepted 14 January 2008

Available online 26 January 2008

Abstract

Transient receptor potential canonical (TRPC) proteins have been proposed to function as plasma membrane Ca²⁺ channels activated by store depletion and/or by receptor stimulation. However, their role in the increase in cytosolic Ca²⁺ activated by contractile agonists in vascular smooth muscle is not yet elucidated. The present study was designed to investigate the functional and molecular properties of the Ca²⁺ entry pathway activated by endothelin-1 in primary cultured aortic smooth muscle cells. Measurement of the Ca²⁺ signal in fura-2-loaded cells allowed to characterize endothelin-1-evoked Ca²⁺ entry, which was resistant to dihydropyridine, and was blocked by 2-aminoethoxydiphenylborate (2-APB) and micromolar concentration of Gd³⁺. It was not activated by store depletion, but was inhibited by the endothelin ET_A receptor antagonist BQ-123, and by heparin. On the opposite, thapsigargin-induced store depletion activated a Ca²⁺ entry pathway that was not affected by 2-APB, BQ-123 or heparin, and was less sensitive to Gd³⁺ than was endothelin-1-evoked Ca²⁺ entry. Investigation of the gene expression of TRPC isoforms by real-time RT-PCR revealed that TRPC1 was the most abundant. In cells transfected with TRPC1 small interfering RNA sequence, TRPC1 mRNA and protein expression were decreased by 72±3% and 86±2%, respectively, while TRPC6 expression was unaffected. In TRPC1 knockdown cells, both endothelin-1-evoked Ca²⁺ entry and store-operated Ca²⁺ entry evoked by thapsigargin were blunted. These results indicate that in aortic smooth muscle cells, TRPC1 is not only involved in Ca²⁺ entry activated by store depletion but also in receptor-operated Ca²⁺ entry, which requires inositol (1,4,5) triphosphate receptor activation.

© 2008 Elsevier B.V. All rights reserved.

Keywords: TRPC [Transient receptor potential canonical]; Endothelin-1; Calcium; Vascular smooth muscle cell

1. Introduction

Intracellular calcium is considered as an important messenger in the control of vascular smooth muscle contractile tone. Activator Ca²⁺ can be released from intracellular stores or can enter the cell from the extracellular space through several types of ion channels. In vascular smooth muscle cell, two main classes of plasmalemmal Ca²⁺ channels have been identified based on the voltage sensitivity of the gating process. Voltage-operated Ca²⁺ channels (VOC) are highly selective for Ca²⁺. They have been widely studied, and their molecular structures have been iden-

tified (Catterall, 2000). The prominent role played by a second group of Ca²⁺ channels that are not activated by membrane depolarisation, has been recognised more recently. Most of them have non-selective cation conductance. They are resistant to dihydropyridines, the well-known inhibitors of L-type VOC, and no reliable selective antagonist is available (Albert and Large, 2006; Beech et al., 2004; Inoue et al., 2003).

The mechanisms of activation and molecular composition of non-selective cation channels have not yet been conclusively identified. In most cells, depletion of intracellular Ca²⁺ stores is pivotal for Ca²⁺ entry commonly termed capacitive Ca²⁺ entry (Berridge, 1995; Putney et al., 2001). Thapsigargin and cyclopiazonic acid are often used to study this pathway because they selectively inhibit the active uptake of Ca²⁺ into the sarcoplasmic reticulum via Ca²⁺-ATPase pump, allowing the stores to be passively depleted, without receptor activation. The

* Corresponding author. Laboratoire de Physiologie Cellulaire, UCL 5540, Avenue Hippocrate 55, B 1200, Bruxelles, Belgium. Tel.: +32 2 764 55 49; fax: +32 2 764 55 80.

E-mail address: Nicole.Morel@uclouvain.be (N. Morel).

capacitative pathway is not however, the only pathway through which Ca^{2+} can enter cells in response to receptor activation. Non-selective cation channels are also activated in response to a signal generated by a range of intracellular messengers released after the binding of an agonist to its receptor including diacylglycerol (Albert and Large, 2006; Helliwell and Large, 1997), arachidonic acid (Munaron et al., 1997; Shuttleworth et al., 2004), inositol (1,4,5) triphosphate (IP_3) (Dong et al., 1995). The later channels have been called “receptor-operated channels or ROC”, in contrast to “store-operated channels or SOC”. However, whether this classification reflects distinct molecular entities is not yet determined.

The canonical transient receptor potential TRPC proteins have been proposed to form non-selective cation channels and considerable research has been carried out on the seven members of this family. RT-PCR analysis has revealed the expression of TRPC1, 4, 5, and 6 mRNA in vascular smooth muscle, including cerebral arteries (Bergdahl et al., 2005), aorta (Xu and Beech, 2001), mesenteric resistance artery (Hill et al., 2006), and pulmonary artery (McDaniel et al., 2001; Sweeney et al., 2002; Wang et al., 2004; Yu et al., 2003).

Several reports have proposed that TRPC1 forms SOC in vascular smooth muscle cell, as in several other cell types (Beech, 2005). TRPC1 specific antibody inhibits store-operated Ca^{2+} influx in human, mouse and rabbit arterial smooth muscle cells (Xu and Beech, 2001). TRPC1 antisense oligonucleotides inhibit SOC in pulmonary artery cell line (Sweeney et al., 2002), while in rat cerebral artery in organ culture, increase in TRPC1 expression is associated with up-regulated SOC activity (Bergdahl et al., 2005). Similarly, overexpression of TRPC1 in pulmonary artery increases capacitative Ca^{2+} entry (Kunichika et al., 2004). In pulmonary artery smooth muscle cell as in the stable A7r5 cell line, (small interfering) siRNA-mediated knockdown of TRPC1 selectively inhibits thapsigargin-activated Ca^{2+} entry (Brueggemann et al., 2006; Lin et al., 2004).

On the other hand, the TRPC3/6/7 subfamily is generally proposed to form ROC. TRPC6 is activated by angiotensin II in rabbit mesenteric artery (Saleh et al., 2006), and by $\alpha 1$ -adrenergic agonist in rabbit portal vein (Inoue et al., 2001). In A7r5 cell line, Ca^{2+} current activated by Arg-vasopressin shares kinetic and pharmacological properties with heterologously expressed TRPC6 channel protein (Jung et al., 2002), and is suppressed by dominant-negative mutant TRPC6 (Maruyama et al., 2006). In rabbit ear artery, noradrenaline activates TRPC3 channels. TRPC3 is also activated by UTP in cerebral arteries (Reading et al., 2005) or, in association with TRPC7, by endothelin-1 in rabbit coronary artery (Peppiatt-Wildman et al., 2007).

The mechanism(s) of activation of Ca^{2+} entry induced by store depletion or receptor activation in vascular smooth muscle cells and their relative contribution to Ca^{2+} signalling are still not defined. One difficulty probably arises from the differences between vascular beds, that could be related to the expression of different TRPC isoforms. Moreover, many studies reported in literature were performed in overexpression systems, and their conclusions cannot be translated to native cells since the composition of the channels and by consequence their properties,

depend on the relative expression of the TRPC proteins (Putney, 2004; Vazquez et al., 2003).

Discrepancy in the responses to vasopressin in A7r5 cells is a good example of the conflicting results that are found in literature: vasopressin has been reported to activate non-capacitative Ca^{2+} entry (Broad et al., 1999; Jung et al., 2002), to activate capacitative Ca^{2+} entry (Brueggemann et al., 2005; Brueggemann et al., 2006) or to reciprocally activate capacitative and non-capacitative Ca^{2+} entry (Moneer et al., 2005; Moneer and Taylor, 2002). These puzzling results are suggested to be related to different expression in TRPC subtypes in variant cell lines: non-capacitative entry is observed in cells expressing TRPC6 (Jung et al., 2002), while TRPC1 is involved in capacitative Ca^{2+} entry (Brueggemann et al., 2006; Moneer et al., 2005).

The present study was designed to characterize the Ca^{2+} entry pathway activated by contractile agonist in rat aortic SMC and to investigate the role of TRPC1 in the response to agonist. The potent vasoconstrictor endothelin-1 was used to stimulate aortic cells. Endothelin-1 binds to endothelin ET_A receptor on vascular smooth muscle cells (VSMC) (Oonuma et al., 2000) and induces an increase in intracellular Ca^{2+} responsible for the development of contraction through the activation of non-selective cation channels (Miwa et al., 2005). Receptor-activated Ca^{2+} entry evoked by endothelin-1 was compared to Ca^{2+} entry activated by store depletion evoked by treatment of the cells with thapsigargin. Results indicated that, in aortic smooth muscle cells, endothelin-1 activates a Ca^{2+} entry pathway that is distinct from SOC and requires IP_3 receptor activation. Inhibition of TRPC1 expression in cells transfected with TRPC1 small interfering RNA sequence abolished endothelin-1 activated Ca^{2+} entry, suggesting that TRPC1 is an indispensable element of ROC in vascular smooth muscle.

2. Materials and methods

All procedures followed were in accordance with institutional guidelines.

2.1. Materials

Fura-2-AM, thapsigargin, endothelin-1, endothelin ET_A receptor antagonist BQ-123, 2-aminoethoxydiphenylborate (2-APB), 1,6-bis(cyclohexyloximinocarbonylamino) hexane (RHC-80267), 3-[(4-octadecyl)benzoyl] acrylic acid (OBAA) were purchased from Calbiochem. Fura-2 acid was from Molecular Probes. All other reagents were purchased from Sigma. Commercially available antibodies were rabbit anti-TRPC1 antibody (Alomone, Jerusalem, Israel), mouse anti- α -smooth muscle actin monoclonal antibody, mouse anti-von Willebrand factor (vWF) and monoclonal antibody mouse anti-rabbit FITC (fluorescein isothiocyanate) secondary antibody were purchased from Dako A/S (Denmark).

2.2. Cell culture

Aorta was isolated from male Wistar rat weighing 150–200 g. Aorta was cleaned from adherent tissue and the endothelium was

mechanically removed by gently rubbing the lumen of the artery with forceps' tips. Pieces of aorta (2 mm²) were cultured on 15-mm round glass coverslips coated with poly-L-lysine (10 µg/ml) in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 50 units/ml penicillin, 50 µg/ml streptomycin and 2 mM glutamine in an incubator at 37 °C with humidified 5% CO₂. Cells migrated from the pieces of aorta after 2–3 days. Aortic pieces were then removed and cells were left to proliferate for 5 days. They were used at 80% of confluence. Aortic smooth muscle cell primary culture will be further denominated VSMC.

2.3. siRNA

The siRNA sequence (www.idtdna.com) was as follows: silencing TRPC1-siRNA 5'-CTGGCCAGTCCAGCTC-TAATA-3'. Non-silencing control siRNA was used (Qiagen, Antwerpen, Belgium). The sense strand of each siRNA was labelled at the 3' end with Alexa Fluor 647, to monitor transfection efficiency. VSMC, at 80% confluency, were transfected with siRNA at a final concentration of 5 µg per well (10 cm²) using lipofectamine (Invitrogen). Control cells were treated with lipofectamine alone under the same condition.

After 48 h, transfection efficiency was assessed by comparison with non-transfected cells using fluorescence microscopy (Olympus IX70 microscope).

2.4. Ca²⁺ imaging

VSMC were washed twice with physiological buffered solution (PBS) containing (in mM): NaCl, 137; KCl, 6; CaCl₂, 2; MgCl₂ 1.2; glucose, 10; HEPES, 10; pH 7.4 with Tris, and loaded for 1 h with fura-2-AM (2.5 µM). The coverslips were mounted in a chamber that was placed on the stage of an Olympus IX70 inverted microscope coupled to a CCD camera. Excitation light (340 and 380 nm) was obtained from a Xenon lamp coupled to a monochromator (TILL Photonics). The 510 nm emission was captured by the CCD camera. The images were transmitted to a computer and processed with the TILLvisION software.

10 to 30 cells were selected for analysis. When siRNA transfected cells were used, they were selected on the basis of siRNA conjugated Alexa Fluor 647 fluorescence. Cells were

gently perfused at 37 °C with PBS at a slow speed (2.5 ml/min). Endothelin-1 (10 nM) was used to stimulate the cells. Cells were first superfused with Ca²⁺-free solution (composition as above, without Ca²⁺ and supplemented with 0.1 mM EGTA) for 5 min, and then challenged with the agonist in the Ca²⁺-free solution. Ca²⁺ was thereafter added into the perfusion solution in the continuous presence of endothelin-1.

The endoplasmic reticulum Ca²⁺-ATPase inhibitor, thapsigargin, was used to deplete intracellular stores. Thapsigargin (1 µM) was applied for 5 min in the Ca²⁺-free perfusion solution. Store-operated Ca²⁺ entry was then assessed by adding Ca²⁺ (2 mM) into the perfusion solution. Depletion of intracellular stores was confirmed by the absence of response to endothelin-1 in Ca²⁺-free solution in thapsigargin-treated cells.

The background autofluorescence values at 340 and 380 nm were measured at the end of the experiment in the presence of 5 mM MnCl₂, and subtracted from all 340 and 380 fluorescence values. These corrected fluorescence values were used to calculate the F340/F380 ratio. All values were normalised to the F340/380 ratio measured at the beginning of the experiment.

For Mn²⁺ quenching analysis, fluorescence was measured with excitation light at 360 nm (F360) in fura-2 loaded cells perfused with Mn²⁺-quenching solution containing (in mM): MnCl₂ 0.1, NaCl 137, KCl 6, MgCl₂ 1.2, glucose 10, HEPES 10, EGTA 0.1, pH 7.4. After 30 s, endothelin-1 (10 nM) was added to the Mn²⁺-quenching solution. 10 min later, MnCl₂ (5 mM) was added to measure background autofluorescence. This value was subtracted from all fluorescence data. Mn²⁺ entry evoked by endothelin-1 was assessed from the rate of decrease of fura-2 fluorescence (normalised to the value recorded immediately before the addition of endothelin-1), measured by the slope of the linear regression line of F360 data recorded during the first 30 s after the addition of endothelin-1, expressed as fluorescence arbitrary unit per second (s⁻¹). R² values of the linear regression were between 0.95 and 0.97.

2.5. Microinjection of heparin

To test the effect of heparin on Ca²⁺ signalling, a mixture of low-molecular weight heparin (200 mg/ml) and fura-2 acid (16.6 mM) was injected into VSMC cytoplasm using Femtotips and an Eppendorf Automated Microinjector 5442 system

Table 1
Oligonucleotide sequences of primers used for RT-PCR

Target	Sequence (5'–3')		Amplicon (bp)
	Forward	Reverse	
rTRPC1	ATGATTTTGCCGACCGGAAG	AATCTGCAGTGGGCCCAAAA	143
rTRPC2	CGAGGACGATGCTGATGTAGA	GTTGTAAAGTTCGGGATTGG	217
rTRPC3	TGCTTGTGTTCACCGCTCA	CCCGAGAACCCAGACCATAAT	146
rTRPC4	CGTGGAAAAGGGGACTATG	CGCATCGCCAACATAGACATTGAA	181
rTRPC5	AACCTACTTCGGAGCCAATGTAC	CCGGATTTCACCTAATCTACCTC	158
rTRPC6	GTCGGTGGTCATCACTACAATC	CCACATCCGCATCATCCTCAATT	155
rTRPC7	ATCATCTCGGAAGGGCTGTAC	GCACCTCGGTAGTAGGAGTAC	209
RPL	AGGCACCAGTCGGACCGATA	GAAGCCGCTAGGCAGCATGT	159

TRPC, transient receptor potential canonical.

RPL, ribosomal protein L32.

(Eppendorf; Brinkman Instruments Inc, Westbury, NY, USA). Injection time and intrapipette pressure were respectively: 0.2 s and 150 hPa. After injection, fura-2 injected cells for which the green signal was visible were examined for Ca^{2+} measurement.

2.6. Real-time RT-PCR

Total RNA was isolated from VSMC and from freshly isolated intact or endothelium-denuded rat aorta using the Trizol Isolation Reagent (Invitrogen), and treated with DNase I (Invitrogen). The RNA sample was additionally purified by isopropanol precipitation and its concentration determined by measuring absorbance at 260 nm. DNase-treated RNA samples were reverse transcribed into cDNA by using Superscript III (Invitrogen).

PCR primers were designed based on published sequences in GenBank (Table 1).

Real-time RT-PCR (iCycler; BioRad, Hercules, CA, USA) analyses were performed in duplicate with 200 nM of both sense and antisense primers in a final volume of 25 μl using Supermix (BioRad). PCR conditions were settled as incubation at 94 °C for 3 min, followed by 40 cycles of 30 s at 95 °C, 30 s at 61 °C, and 1 min at 72 °C. The melting temperature of PCR product was checked at the end of each PCR by recording SYBR Green fluorescence increase upon slowly renaturing DNA. A control PCR without template DNA was performed in each experiment. The melting curves of all PCR products showed single peaks, indicating the specificity of the primers. A control PCR without RT was performed in each experiment. We normalised mRNA expression of TRPC by ribosomal protein L32 (RPL32) as a housekeeping gene. Regression analyses of the Ct (threshold cycle) values of the standard dilution series were used to determine the amplification efficiency. Efficiencies and slopes were nearly similar and close to 100% and -3.33 , respectively. The standardized ratio (TRPC mRNA/RPL mRNA) will be referred to as the relative amount of TRPC mRNA.

The expression of endothelial nitric oxide synthase (eNOS) and of vWF mRNA was assessed by semi-quantitative radioactive RT-PCR, as described (Krensek et al., 2006).

2.7. Immunofluorescence

Cells were fixed with paraformaldehyde 4% (v/v) for 15 min at room temperature and permeabilized thereafter with 1% Triton X-100 (v/v) in Tris-buffered saline (TBS; Tris-HCl 50 mM, NaCl 150 mM, pH 7.4) for 15 min. Non-specific immunostaining was prevented by a 1 h incubation in a TBS solution containing 3% non-fat dry milk at 37 °C. For TRPC1, fixed cells were then successively incubated in TBS/milk 3% for 1 h at room temperature with primary rabbit anti-TRPC1




Fig. 1. Characterization of the Ca^{2+} signal evoked by endothelin-1 and thapsigargin in aortic smooth muscle cells (VSMC). A. Effect of endothelin-1 in fura-2-loaded VSMC. Left panel: Typical experimental trace of the F340/F380 ratio. Cells were perfused with Ca^{2+} -free solution and endothelin-1 (ET-1, 10 nM) as indicated. Right panel: Mean values of the maximum increase in Ca^{2+} signal induced by endothelin-1 in the absence and presence of Ca^{2+} ($n=5$). B. Effect of thapsigargin in fura-2 loaded VSMC. Left panel: Typical experimental trace of the F340/F380 ratio. Cells were perfused with Ca^{2+} -free solution and thapsigargin (TG, 1 μM) as indicated. Right panel: Mean values of the maximum increase in Ca^{2+} signal induced by TG in the absence and presence of Ca^{2+} ($n=7$). C. Effect of BQ-123 on endothelin-1-evoked Ca^{2+} signal in fura-2 loaded VSMC. Left panel: Typical experimental trace of the F340/F380 ratio. Cells were perfused with Ca^{2+} -free solution and endothelin-1 (ET-1, 10 nM) as indicated. BQ-123 (0.5 μM) was added in the perfusion solution after completion of Ca^{2+} release. Right panel: Mean values of the maximum change in Ca^{2+} signal induced by endothelin-1 in the absence and presence of Ca^{2+} ($n=5$). D. Effect of BQ-123 on thapsigargin-evoked Ca^{2+} signal in fura-2 loaded VSMC. Left panel: Typical experimental trace of the F340/F380 ratio. Cells were perfused with Ca^{2+} -free solution and thapsigargin (TG, 1 μM) as indicated. BQ-123 (0.5 μM) was added in the perfusion solution after completion of Ca^{2+} release. Right panel: Mean values of maximum increase in Ca^{2+} signal induced by TG ($n=5$).

antibody (1/200), rinsed three times with TBS, and incubated for 1 h with a secondary anti-rabbit IgG FITC-conjugated antibody (1/500). Nuclei were stained for 3 min with the nuclear dye DAPI (4'-6-diamidino-2-phenylindole) (1/5000). After three rinses, preparations were mounted in Fluoprep medium (BioMerieux) and examined using an Olympus IX70 inverted microscope. Excitation lights were 488 and 400 nm for FITC and DAPI, respectively. Digital images were acquired using appropriate filters and combined using the TILLvision software. To quantify the fluorescence intensity of TRPC1, the mean immunofluorescence intensity of cells was determined by measuring the fluorescence intensity using TILLvision software.

2.8. Statistical analysis

Data are expressed as means \pm S.E.M. Number of experiments refers to the number of determinations performed with different cell cultures. Fura2 F340/F380 traces are mean values from 10 to 30 cells. Statistical analysis was performed by Student *t* test, or by analysis of variance, and Bonferroni's post test as indicated. Differences were considered to be significant when *P* was lower than 0.05. Log value of IC₅₀ was calculated by non-linear fitting of experimental data, using the logistic equation with variable slope (Graph Pad Prism).

3. Results

3.1. Characterization of the cell culture

More than 95% of the cells stained positively for the muscular marker smooth muscle α -actin. None was positive for the endothelial marker, Von Willebrand factor (supplemental data). Absence of endothelial cells in the culture was confirmed by assessing the expression of eNOS mRNA by RT-PCR analysis. eNOS mRNA was not detected in primary culture of VSMC,

while under the same condition marked expression was observed in intact aorta (supplemental data). Consequently, our cell culture was confirmed to be free of contamination with endothelial cells.

3.2. Characterization of receptor and store-operated Ca^{2+} entry

Receptor-evoked Ca^{2+} entry was estimated using endothelin-1. In the absence of extracellular Ca^{2+} , endothelin-1 (10 nM) evoked a rapid but transient increase in Ca^{2+} signal (Fig. 1A). The Ca^{2+} peak observed in Ca^{2+} -free solution was abolished after




Fig. 2. Effect of 2-APB and Gd^{3+} on endothelin-1 and thapsigargin-evoked Ca^{2+} entry. A. Typical experimental traces showing the F340/F380 ratio in fura-2 loaded VSMC stimulated with endothelin-1. Cells were perfused with Ca^{2+} -free solution and stimulated with endothelin-1 (ET-1, 10 nM) as indicated. 2-APB (300 μM) or solvent (control) was added in perfusion solution after completion of Ca^{2+} peak, as indicated by the horizontal bar. Traces are representative of at least 4 experiments. B. Typical experimental traces showing F340/F380 ratio in fura-2 loaded VSMC stimulated with thapsigargin. Cells were perfused with Ca^{2+} -free solution as indicated and Ca^{2+} release was evoked with thapsigargin (TG, 1 μM). 2-APB (300 μM) or solvent (control) was added in perfusion solution after completion of Ca^{2+} release, as indicated by the horizontal bar. Traces are representative of at least 4 experiments. C. Effect of 2-APB on Ca^{2+} entry induced by endothelin-1 or thapsigargin. The increase in F340/F380 ratio measured after addition of Ca^{2+} in the presence of 2-APB was expressed as a percentage of the value measured in the absence of 2-APB (control). Data are mean values \pm S.E.M. from 4 independent determinations. D. Effect of Gd^{3+} on Ca^{2+} entry induced by endothelin-1 or thapsigargin. Cells were stimulated with either endothelin-1 (ET-1, 10 nM) or thapsigargin (TG, 1 μM) in Ca^{2+} -free solution. Ca^{2+} entry was evoked by the addition of Ca^{2+} into the perfusion solution. Gd^{3+} (3 nM–3 μM) was added to the perfusion solution after completion of Ca^{2+} release. The increase in Ca^{2+} signal measured after addition of Ca^{2+} in the presence of Gd^{3+} was expressed as a percentage of the value measured in the absence of Gd^{3+} (control). Data are mean values \pm S.E.M. from 3–4 experiments. Curves were drawn by non-linear curve fitting of the experimental data.




Fig. 3. Effect of heparin on endothelin-1 and thapsigargin-evoked Ca^{2+} signal in fura-2-loaded VSMC. Typical experimental traces showing the fura-2 fluorescence F340/F380 ratio in cells injected with low-molecular weight heparin and fura-2 acid. A. Cells were perfused with Ca^{2+} -free solution and stimulated with endothelin-1 (ET-1, 10 nM) as indicated. Ionomycin (4 μM) was added at the end of the experiment. B. Cells were perfused with Ca^{2+} -free solution and stimulated with thapsigargin (TG, 1 μM) as indicated. Traces are representative of at least 4 experiments.

treatment of the cells with thapsigargin (data not shown), suggesting that it reflected the release of internal Ca^{2+} . Re-addition of Ca^{2+} into the perfusion solution in the continuous presence of the agonist increased the Ca^{2+} signal. The amplitude of the response evoked by the addition of Ca^{2+} measured at the maximum of the Ca^{2+} signal, was markedly smaller than the peak response obtained in Ca^{2+} -free solution (ΔR was 1.05 ± 0.14 and 0.336 ± 0.047 in Ca^{2+} -free medium and after addition of Ca^{2+} , respectively, $n=5$). Preincubation of VSMC with the endothelin ET_A and ET_B receptor antagonist bosentan (7 μM), or with the endothelin ET_A receptor antagonist BQ-123 (0.5 μM) (Davenport and Battistini, 2002), completely abolished endothelin-1 evoked Ca^{2+} signal (data not shown). When added immediately after the peak of Ca^{2+} release induced by endothelin-1 in Ca^{2+} -free solution, the endothelin ET_A receptor antagonist BQ-123 prevented the increase in Ca^{2+} signal evoked by adding Ca^{2+} into the external solution (Fig. 1C). The same effect was observed with bosentan (data not shown).

Store-operated Ca^{2+} signal was measured by using thapsigargin to deplete SR Ca^{2+} stores. Application of thapsigargin (1 μM) in Ca^{2+} -free solution produced a transient increase in Ca^{2+} signal, which amplitude was variable from cell to cell, and in average smaller than the Ca^{2+} peak evoked by endothelin-1 (ΔR was 0.267 ± 0.061 , $n=7$) (Fig. 1B). After 5 min in thapsigargin – Ca^{2+} -free solution, the re-addition of Ca^{2+} into the perfusion solution increased the Ca^{2+} signal above the basal value recorded before perfusion with Ca^{2+} -free solution, reflecting the activation of store-operated Ca^{2+} entry (mean ΔR was 0.368 ± 0.062 , $n=7$). The increase in Ca^{2+} signal resulting from thapsigargin-evoked store depletion was unaffected by the endothelin-1 receptor

antagonists BQ-123 (0.5 μM) (Fig. 1D) or bosentan (7 μM , data not shown).

To further characterize the Ca^{2+} entry activated by endothelin-1 and by thapsigargin-evoked store depletion, we tested their sensitivity to the inhibitor of IP_3 receptors 2-APB and the inhibitor of TRPC Gd^{3+} . Inhibitors were applied after completion of the Ca^{2+} release process by endothelin-1 or thapsigargin, in order to prevent any effect of the inhibitors on the SR Ca^{2+} content. Fig. 2A–C shows that 2-APB (300 μM) abolished endothelin-1 evoked Ca^{2+} entry, but did not affect Ca^{2+} entry activated after thapsigargin-evoked store depletion. The effect of 2-APB on endothelin-1 evoked Ca^{2+} entry was concentration-dependent; $\log(\text{IC}_{50})$ value was -4.65 ± 0.14 . Gd^{3+} (10 nM–3 μM) depressed both endothelin-1 and thapsigargin-evoked Ca^{2+} entry (Fig. 2D). However, endothelin-1 evoked Ca^{2+} entry was significantly more sensitive to Gd^{3+} than was thapsigargin-evoked Ca^{2+} entry: Gd^{3+} $\log(\text{IC}_{50})$ values were -7.54 ± 0.05 and -7.04 ± 0.06 , respectively ($P < 0.01$). Neither endothelin-1 nor thapsigargin-evoked Ca^{2+} entry was affected by the L-type Ca^{2+} channel blocker nimodipine (1 μM) (data not shown).

To investigate the involvement of IP_3 receptor in the activation of Ca^{2+} entry, cells were injected with heparin, which blocks IP_3 receptor (Yamamoto et al., 1990), together with fura-2 acid. In heparin-injected cells, endothelin-1 did not produce any change in Ca^{2+} signal in Ca^{2+} -free solution and after re-addition of Ca^{2+} into the perfusion solution (Fig. 3A). The large increase in F340/F380 ratio evoked by ionomycin at the end of the experiment indicated that the absence of response to endothelin-1 was not caused by damage to the cells, or defect in fura-2 signalling. On the opposite, heparin did not affect either Ca^{2+} release evoked by thapsigargin in Ca^{2+} free solution, or Ca^{2+} entry activated by addition of Ca^{2+} after intracellular Ca^{2+} store depletion (Fig. 3B).

Activation of phospholipase C following endothelin receptor stimulation also results in the production of DAG. Direct activation of Ca^{2+} entry by DAG has been demonstrated (Helliwell and Large, 1997; Hofmann et al., 1999; Sydorenko et al., 2003). OAG was used to investigate the involvement of DAG in the Ca^{2+} entry activated by endothelin-1 in VSMC. OAG (100 μM) was first applied in Ca^{2+} free solution during 5 min, before Ca^{2+} (2 mM) was added into the solution. Neither in Ca^{2+} free solution, not after addition of Ca^{2+} , did OAG produce an increase in cytosolic Ca^{2+} .




Fig. 4. Real-time RT-PCR analysis of TRPC1–7 in rat endothelium-denuded aorta and in primary culture of aortic smooth muscle cells. The mRNA levels were first adjusted to RPL, then normalised to the level of TRPC1 mRNA in the same sample, set at 100%. Data are means \pm S.E.M. from 4 independent experiments.

Involvement of arachidonic acid in the activation of Ca^{2+} entry by endothelin-1 was assessed with a combination of the DAG lipase inhibitor RHC-80267 and of the phospholipase A2 inhibitor OBAA. At 10 μM , RHC-80267 and OBAA did not affect the Ca^{2+} entry evoked by endothelin-1 (ΔR was 0.335 ± 0.032 and 0.372 ± 0.071 , $n=3$ experiments, in the presence and in the absence of the inhibitors, respectively).

3.3. TRPC mRNA expression

The expression of TRPC1–7 isoforms was evaluated using real-time RT-PCR in VSMC and endothelium-denuded aorta. Preliminary experiments indicated that TRPC2, expressed in the vomeronasal organ used as positive control, was detected neither in VSMC nor in aorta (data not shown). All other TRPC isoforms were expressed in VSMC and in aorta (Fig. 4). TRPC1 was the most abundant in cultured aortic cells and in aorta. TRPC6 was expressed at intermediate levels, whereas TRPC3,




Fig. 5. Effect of TRPC1-siRNA on TRPC1 expression in VSMC. A–B. Real-time RT-PCR quantification of the mRNA expression of TRPC1 (A) and TRPC6 (B). The mRNA levels were first adjusted to housekeeping gene RPL mRNA, then normalised to the level of expression in cells transfected with non-silencing-siRNA set at 100%. mRNA expression was calculated from 4 independent experiments, *indicates significant difference ($n=4$). C. Mean value of anti-TRPC1 labelling intensity in VSMC transfected with non-silencing-siRNA ($n=26$ images from 3 independent experiments) and in VSMC transfected with TRPC1-siRNA ($n=39$ images from 4 independent experiments). Data were normalised to the pixel intensity measured in cells transfected with non-silencing-siRNA. *indicates significant difference ($P<0.01$, versus cells transfected with non-silencing-siRNA).




Fig. 6. Effect of the inhibition of TRPC1 expression on endothelin-1 induced Ca^{2+} signal. A. Typical traces of F340/F380 ratio in fura-2-loaded VSMC stimulated with endothelin-1. Traces obtained in TRPC1-siRNA transfected cells and in non-silencing-siRNA transfected cells are superimposed. Cells were perfused with Ca^{2+} -free solution and endothelin-1 (ET-1, 10 nM) as indicated. Traces are means from 10 and 15 cells and are representative of at least 4 experiments. B. Mean values of the increase in F340/F380 ratio evoked by endothelin-1 in the absence of Ca^{2+} . C. Mean values of the increase in F340/F380 ratio evoked by the re-addition of Ca^{2+} (2 mM) into Ca^{2+} -free solution in the presence of endothelin-1. Control non-transfected VSMC ($n=5$ experiments), VSMC transfected with non-silencing-siRNA ($n=4$ experiments), TRPC1-siRNA transfected VSMC ($n=4$ experiments). *indicates significant difference versus control ($P<0.01$).

TRPC4 and TRPC5 expressions were low. TRPC7 was hardly detectable.

3.4. Effect of inhibition of TRPC1 expression by siRNA on receptor and store-operated Ca^{2+} entry

As shown in Fig. 5 (A–B), real-time RT-PCR analysis indicated that transfection of VSMC with TRPC1-siRNA inhibited mRNA expression of TRPC1 by $72 \pm 3\%$ ($n=4$ different cell cultures), while the expression of TRPC6 was unaffected.

Protein expression of TRPC1 was estimated by immunocytochemistry (Fig. 5C and supplemental data). Quantification of the TRPC1 labelling indicated that TRPC1 protein expression

was decreased by $84 \pm 13\%$ in TRPC1-siRNA transfected cells, compared with cells transfected with non-silencing-siRNA ($n=4$).

The function of TRPC1 in the activation of Ca^{2+} signal was assessed in siRNA transfected cells loaded with fura-2. VSMC transfection with TRPC1-siRNA or with non-silencing-siRNA did not affect the intracellular Ca^{2+} release evoked by endothelin-1 in Ca^{2+} -free solution (Fig. 6). The Ca^{2+} signal evoked by re-addition of Ca^{2+} into the Ca^{2+} -free solution was nearly abolished in TRPC1-siRNA transfected cells, while it was not different in cells transfected with non-silencing-siRNA and in control non-transfected cells (Fig. 6).

In order to provide a direct estimate of the activation of a Ca^{2+} channel by endothelin-1, the effect of endothelin-1 on cation entry was monitored by measuring the quenching of fluorescence upon excitation at 360 nm (F360) evoked by Mn^{2+} . Mn^{2+} is known to permeate through cation channels in the membrane, and when in the cell, to bind to fura-2 and to quench its fluorescence. The rate of fura-2 quenching by Mn^{2+} upon excitation at the isosbestic point of fura-2 (360 nm) is a direct indication of the cation entry into the cell since Mn^{2+} is not handled by pumps and transporters (Missiaen et al., 1990). Perfusion of the cells with the Mn^{2+}




Fig. 7. Effect of TRPC1 inhibition on endothelin-evoked cation entry Ca^{2+} entry was estimated by the quenching of fluorescence at 360 nm (F360) by Mn^{2+} in fura-2-loaded cells. A. Decrease in F360 after addition of endothelin-1 (10 nM) in Ca^{2+} -free Mn^{2+} -containing solution, in control non-transfected cells, in TRPC1-siRNA transfected cells and in non-transfected cells preincubated with BQ-123 (0.5 μM). F360 values were normalised to the fluorescence measured at the time of endothelin-1 addition. Traces are means from 12–20 cells, measured in one experiment. B. Mean values of the rate of decrease of F360 measured during the first 30 s after the addition of endothelin-1. Data are means from 4 experiments, except for non-silencing-siRNA transfected cells, where data are means from 3 experiments. *indicates significant differences ($P < 0.01$).




Fig. 8. Effect of inhibition of TRPC1 expression on thapsigargin-evoked Ca^{2+} signal. A. Typical experimental traces showing the effect of thapsigargin on F340/F380 ratio in fura-2 loaded VSMC. Traces obtained in cells transfected with non-silencing-siRNA and in TRPC1-siRNA transfected cells are superimposed. Perfusion with Ca^{2+} -free solution and thapsigargin (TG, 1 μM) were applied as indicated. Traces are averages from 14–20 cells and are representative of at least 4 experiments. B. Mean value of the increase in F340/F380 ratio evoked by the re-addition of Ca^{2+} (2 mM) into Ca^{2+} -free solution after thapsigargin-evoked intracellular Ca^{2+} release. Data are means \pm S.E.M. from 4 experiments. *indicates significant difference versus control cells ($P < 0.01$).

quenching solution induced a slow decrease in F360 fluorescence, that could be analysed by linear regression to approximate the rate of F360 quenching. The slope of the decrease in F360 was $(-0.88 \pm 0.29) \cdot 10^{-3} \text{ s}^{-1}$ ($n=35$ cells) and was not different in cells transfected with TRPC1-siRNA, non-silencing-siRNA, or in cells treated by the endothelin ET_A receptor antagonist BQ-123. Addition of endothelin-1 in the perfusion markedly increased the quenching rate of F360. The rate of Mn^{2+} entry was estimated from the slope of the fluorescence intensity decrease during the first 30 s after the addition of endothelin-1. As shown in Fig. 7, endothelin-1 caused an 8-fold increase in the quenching rate of F360, which was suppressed in the presence of the endothelin ET_A receptor antagonist BQ123 ($P < 0.05$ versus endothelin-1). Endothelin-1-evoked F360 quenching was significantly slowed down in cells transfected with TRPC1-siRNA compared to non-transfected cells, while in cells transfected with non-silencing-siRNA, the slope of F360 decrease after addition of endothelin-1 was not different from that observed in non-transfected cells (Fig. 7).

The functional role of TRPC1 in store-operated Ca^{2+} entry in VSMC was assessed by measuring Ca^{2+} entry after store depletion with thapsigargin in cells transfected with TRPC1-siRNA. Fig. 8 shows that store-operated Ca^{2+} entry was depressed by $80 \pm 6\%$ in cells transfected with TRPC1-siRNA, compared to non-

transfected cells but was not affected by cell transfection with non-silencing-siRNA ($n=4$).

4. Discussion

The present study shows that in VSMC, TRPC1 is not only involved in a store-operated entry of Ca^{2+} , but also in a receptor-activated Ca^{2+} entry pathway that requires IP_3 receptor activation.

We used primary cultured aortic smooth muscle cells. Culture was principally composed of smooth muscle cells without contamination by endothelial cells, based on the absence of significant expression of markers of endothelial cells (eNOS, von Willebrand factor). This observation is important since endothelial cells in culture have been shown to express TRPC1–6 to varying degrees (Nilius et al., 2003; Tiruppathi et al., 2002). Culture has been reported to modify the expression of several ion channels (Bergdahl et al., 2005). Nevertheless, the comparison of the relative levels of TRPC transcripts in VSMC and in isolated, endothelium-denuded, aorta showed a similar pattern of expression of the different TRPC isoforms, indicating that VSMC is a good model for the study of Ca^{2+} entry pathways. In agreement with Facemire et al. (2004), our results demonstrated that rat aorta and VSMC expressed mRNA for TRPC1, 3, 4, 5, 6 (Fig. 4). However, in contrast to this earlier report, we found that TRPC1 predominated, and that TRPC6, although it was also abundant, showed a significantly lower expression than TRPC1, in both VSMC and isolated aorta.

4.1. Endothelin-1 activates a calcium entry pathway distinct from capacitative calcium entry

Endothelin-1 was used to investigate the properties of receptor-activated Ca^{2+} entry in VSMC. In Ca^{2+} -free solution, endothelin-1 evoked a rapid and transient increase in Ca^{2+} signal. Inhibition of this Ca^{2+} peak after treatment with thapsigargin in Ca^{2+} free solution indicated that it resulted from Ca^{2+} release from the SR. This was confirmed by the abolition of the Ca^{2+} peak after inhibiting the IP_3 receptor with heparin. The addition of Ca^{2+} in the endothelin-1-containing perfusion solution produced a sustained increase in cytosolic Ca^{2+} , which was resistant to blockers of voltage-dependent Ca^{2+} channels, in agreement with the activation by endothelin-1 of cation channels (Iwamuro et al., 1999; Kawanabe et al., 2002a; Peppiatt-Wildman et al., 2007). This increase in Ca^{2+} signal reflected an entry of Ca^{2+} into the cell, as confirmed by using extracellular Mn^{2+} as a surrogate ion for Ca^{2+} . Quenching rate of fura-2 fluorescence by Mn^{2+} was increased by endothelin-1, and this effect was inhibited by the endothelin ET_A receptor antagonist BQ-123.

An important observation was that endothelin-1-evoked Ca^{2+} entry was abolished when the endothelin ET_A receptor antagonist BQ-123 was applied after the process of Ca^{2+} release was completed, indicating that store depletion is not sufficient to activate Ca^{2+} entry, which required the occupation of the endothelin ET_A receptor by the agonist. Blockade of the channel by the endothelin ET_A receptor antagonist BQ-123 might be ruled out because BQ-123 did not affect Ca^{2+} entry activated after store depletion with thapsigargin, and because the same

effect was obtained with the mixed endothelin ET_A/ET_B receptor antagonist bosentan. This observation is in agreement with the report that in rabbit cerebral arteriolar smooth muscle, endothelin-1-induced Ca^{2+} influx is separate from any capacitative Ca^{2+} entry mechanism because its amplitude remains the same even when sarcoplasmic reticulum has previously been depleted of Ca^{2+} (Guibert and Beech, 1999). Controversially, in rat aortic cells, endothelin-1 has been reported to activate both capacitative and non-capacitative Ca^{2+} entry, on the basis of the sensitivity of the Ca^{2+} response to SK&F 96365 and LOE 908 (Kawanabe et al., 2002a; Zhang et al., 1999).

A reciprocal effect of vasopressin on capacitative and non-capacitative Ca^{2+} entry has been reported in A7r5 cells. In those cells, capacitative Ca^{2+} entry is rapidly activated when vasopressin is removed from the bathing solution (Moneer and Taylor, 2002), an observation that has not been confirmed in other A7r5 cell lines variants (Brueggemann et al., 2005). Inhibition of capacitative Ca^{2+} entry by endothelin-1 did not occur in VSMC, since the addition of the endothelin ET_A receptor antagonist BQ-123 did not evoke any increase in Ca^{2+} signal.

4.2. Endothelin-1-activated calcium entry requires IP_3 binding to the IP_3 receptor

A second important property of endothelin-1-evoked Ca^{2+} entry was its sensitivity to heparin, which is known to block IP_3 receptor (Peppiatt-Wildman et al., 2007). On the other hand, heparin did not affect thapsigargin-induced Ca^{2+} entry. This observation indicates that, unlike store-operated Ca^{2+} entry, Ca^{2+} entry activated by endothelin-1 requires IP_3 binding to its receptor. This is in the line of the observation that endothelin-1-evoked Ca^{2+} entry required the activation of the endothelin ET_A receptor, which results in the G protein-mediated activation of phospholipase C (Kawanabe et al., 2002b).

In coronary artery myocytes, the signal transduction mechanism linking endothelin-1 to activation of cation channel current involves PLC coupled to endothelin ET_A receptor (Peppiatt-Wildman et al., 2007). PLC is also involved in noradrenaline-induced cation channel activation in the rabbit portal vein (Helliwell and Large, 1997) and in angiotensin II in rabbit mesenteric smooth muscle cells (Saleh et al., 2006), but in those cells cation channel conductance was activated by DAG. In coronary artery cells, IP_3 potentiated the response to OAG, an effect that was blocked by heparin (Peppiatt et al., 2003).

The involvement of DAG in the activation of Ca^{2+} entry by endothelin-1 in aortic myocytes is unlikely, because (i) heparin completely blocked endothelin-1 evoked Ca^{2+} entry, (ii) inhibition of DAG degradation with RHC-80267 did not change endothelin-1 evoked Ca^{2+} entry and (iii) OAG did not generate any Ca^{2+} signal. In agreement with the last result, Brueggemann et al. (2006) reported that 100 μM OAG did not activate Isoc current in A7r5 cells.

In several cell types including smooth muscle cells, human platelets and jurkat T lymphocytes, store-operated Ca^{2+} entry is blunted when the activity of phospholipase A2 is inhibited (Broad et al., 1999; Smani et al., 2004), and direct activation of cation channel by arachidonic acid has been reported (Shuttleworth

et al., 2004). In our study, endothelin-1 TRPC1 induced Ca^{2+} entry was not affected by the phospholipase A2 inhibitor OBAA, or by DAG lipase inhibition, which inhibits the release of arachidonic acid from DAG, suggesting that arachidonic acid was not involved in the activation of Ca^{2+} entry by endothelin-1.

4.3. TRPC1 is involved in endothelin-1-activated calcium entry and in capacitative calcium entry

In order to test the hypothesis that TRPC1 contributes to the Ca^{2+} entry pathway activated by endothelin-1, the expression of the channel protein was inhibited by siRNA transfection. Using real-time RT-PCR and immunocytochemistry, we showed that TRPC1-siRNA significantly reduced the expression of endogenous TRPC1, while the level of expression of TRPC6 was not affected.

TRPC1-siRNA transfection of VSMC led to the inhibition of thapsigargin-evoked Ca^{2+} entry. This observation is in agreement with several reports that demonstrate, by different experimental approaches, that TRPC1 functions as store-operated channel (see Introduction). Interestingly, in our study, inhibition of TRPC1 expression markedly blunted endothelin-1-induced Ca^{2+} influx, while Ca^{2+} release was not affected, providing strong evidence that TRPC1 is involved in the Ca^{2+} entry generated by endothelin receptor activation. This was confirmed by measuring the rate of fura-2 fluorescence quenching at 360 nm in the presence of Mn^{2+} , showing that in TRPC1-siRNA transfected cells, quenching of F360 by endothelin-1 was significantly depressed, to a level similar to that observed in the presence of BQ-123 in non-transfected cells. The involvement of TRPC1 in endothelin-1-evoked Ca^{2+} signal is in agreement with the report that in caudal artery, TRPC1 antibody inhibits the contraction evoked by endothelin-1 by 40% (Bergdahl et al., 2003). However, in rabbit coronary artery myocytes, anti-TRPC1 antibody did not inhibit endothelin-1 evoked cation channel activity, while anti-TRPC3 and anti-TRPC7 antibodies markedly inhibited endothelin-1 evoked current (Peppiatt-Wildman et al., 2007).

Taken together the present results indicate that in primary cultured VSMC, TRPC1 contributes to both SOC and ROC-mediated Ca^{2+} entry. Pharmacological tools were used to further characterize those Ca^{2+} entry pathways. Gd^{3+} is widely used to block non-selective cation channels (McFadzean and Gibson, 2002), but has been reported to lack selectivity against VOC, ROC or SOC (Poburko et al., 2004). It blocks TRPC1 (Brueggemann et al., 2006; Zitt et al., 1996), TRPC3 (Albert et al., 2006), TRPC6 channels (Inoue et al., 2001) but activates and potentiates TRPC4/5 (Jung et al., 2003) and TRPV1 (Tousova et al., 2005). We have observed that at concentration as low as 1 μM , Gd^{3+} abolished Ca^{2+} entry activated by endothelin-1 as well as that activated by store depletion. However, Gd^{3+} was two times more potent on endothelin-1-induced Ca^{2+} entry (IC_{50} 40 nM) compared to thapsigargin-activated Ca^{2+} entry (IC_{50} 110 nM). The latter value is in the range of the IC_{50} on SOC (101 nM) reported by Flemming et al. (2003) in cerebral arteriolar smooth muscle cells. Higher concentrations of Gd^{3+} are needed to inhibit cation current activated by α -adrenergic

receptor in rabbit portal vein smooth muscle, which has been shown to be mediated through TRPC6 channel protein (IC_{50} 2 μM) (Inoue et al., 2001), or to inhibit SOC in renal artery, which requires 100 μM Gd^{3+} (Wilson et al., 2002). In A7r5 embryonic aortic cells, capacitative Ca^{2+} entry is irreversibly blocked by low concentration of Gd^{3+} , which does not affect Arg-vasopressin-evoked Ca^{2+} entry (Broad et al., 1999).

Difference in the sensitivity of store depletion and receptor-activated Ca^{2+} entry to blockers was confirmed with 2-APB, which inhibited Ca^{2+} entry activated by endothelin-1, but not store-operated Ca^{2+} entry activated by thapsigargin. This selective effect of 2-APB against endothelin-1 evoked Ca^{2+} entry might be related to the reported effect of the antagonist on IP_3 receptor (Ma et al., 2000; Maruyama et al., 1997; Peppiatt et al., 2003; Soulsby and Wojcikiewicz, 2002). This property has been challenged by the report that 2-APB inhibits TRPC3, 6 and 7 channels by a mechanism not involving IP_3 receptor in HEK293 cells (Lievremont et al., 2005). 2-APB also inhibits ICRAC and store-operated entry in a mutant DT40 cell line in which IP_3 receptors are not expressed (Ma et al., 2001), indicating that IP_3 receptors are not required for 2-APB block of Ca^{2+} entry.

The lack of inhibition of thapsigargin-evoked Ca^{2+} entry by 2-APB is not consistent with 2-APB being regarded as selectively inhibiting the capacitative entry of Ca^{2+} in a variety of different cell types, including A7r5 cells (Brueggemann et al., 2006; Moneer and Taylor, 2002) and vascular smooth muscle (Kumar et al., 2006). Interestingly, in rabbit vena cava, 2-APB does not affect the elevation in intracellular Ca^{2+} following SR store depletion but inhibits the generation of intracellular Ca^{2+} concentration oscillations in response to α 1-adrenoceptor activation (Lee et al., 2002). The molecular target of this compound remains to be further characterized.

Despite the lack of selectivity of the pharmacological inhibitors used, their action confirms that endothelin-1 and store depletion activate distinct Ca^{2+} entry pathways, although both involve TRPC1. Ca^{2+} entry evoked by endothelin-1 and store depletion in VSMC also differed by the mechanism of their activation. The present results indicate that in primary cultured aortic smooth muscle cells, activation of endogenous TRPC1 by endothelin-1 requires IP_3 receptor activation. Several experimental approaches have provided evidence indicating that IP_3 receptor and TRPC1 are physically associated, either directly or through binding partners like Homer or Rho (Lockwich et al., 2000; Mehta et al., 2003; Peppiatt et al., 2003; Rosado and Sage, 2000; Yuan et al., 2003). Such an interaction may be responsible for the activation of TRPC1 by endothelin-1 in VSMC.

The present data show that TRPC1 contributes to both SOC and ROCs in VSMC, which have different pharmacological properties. TRPC channels have been reported to be heteromeric complexes (Maruyama et al., 2006; Strubing et al., 2003; Zagranichnaya et al., 2005). In particular, TRPC1 can associate with TRPC4 or 5 (Hofmann et al., 2002; Strubing et al., 2001) and with TRPC3 (Lintschinger et al., 2000; Liu et al., 2005). Association of different isoforms has been reported to confer distinct physiological and pharmacological properties to the channel (Liu et al., 2005; Trebak et al., 2002). Further studies will have to test whether formation of heteromeric channels

could explain the different functional and pharmacological properties of TRPC1 in VSMC.

Acknowledgements

The authors are grateful to E. Hermans and O. Devuyt for assistance and access to fluorescence microscopy and real-time RT-PCR, and to Greet Vandenberg for her excellent technical assistance. This work was supported by a grant from the Ministère de l'Éducation et de la Recherche Scientifique (Action Concertée n°06/11-339) and from the FRSM (grants n°3.4528.05 and 3.4601.06).

References

- Albert, A.P., Large, W.A., 2006. Signal transduction pathways and gating mechanisms of native TRP-like cation channels in vascular myocytes. *J. Physiol.* 570, 45–51.
- Albert, A.P., Pucovsky, V., Prestwich, S.A., Large, W.A., 2006. TRPC3 properties of a native constitutively active Ca^{2+} -permeable cation channel in rabbit ear artery myocytes. *J. Physiol.* 571, 361–369.
- Beech, D.J., 2005. TRPC1: store-operated channel and more. *Pflügers Arch.* 451, 53–60.
- Beech, D.J., Muraki, K., Flemming, R., 2004. Non-selective cationic channels of smooth muscle and the mammalian homologues of *Drosophila* TRP. *J. Physiol.* 559, 685–706.
- Bergdahl, A., Gomez, M.F., Dreja, K., Xu, S.Z., Adner, M., Beech, D.J., Broman, J., Hellstrand, P., Sward, K., 2003. Cholesterol depletion impairs vascular reactivity to endothelin-1 by reducing store-operated Ca^{2+} entry dependent on TRPC1. *Circ. Res.* 93, 839–847.
- Bergdahl, A., Gomez, M.F., Wihlborg, A.K., Erlinge, D., Eyjolfson, A., Xu, S.Z., Beech, D.J., Dreja, K., Hellstrand, P., 2005. Plasticity of TRPC expression in arterial smooth muscle: correlation with store-operated Ca^{2+} entry. *Am. J. Physiol., Cell Physiol.* 288, C872–C880.
- Berridge, M.J., 1995. Capacitative calcium entry. *Biochem. J.* 312, 1–11.
- Broad, L.M., Cannon, T.R., Taylor, C.W., 1999. A non-capacitative pathway activated by arachidonic acid is the major Ca^{2+} entry mechanism in rat A7r5 smooth muscle cells stimulated with low concentrations of vasopressin. *J. Physiol.* 517, 121–134.
- Brueggemann, L.I., Markun, D.R., Barakat, J.A., Chen, H., Byron, K.L., 2005. Evidence against reciprocal regulation of Ca^{2+} entry by vasopressin in A7r5 rat aortic smooth-muscle cells. *Biochem. J.* 388, 237–244.
- Brueggemann, L.I., Markun, D.R., Henderson, K.K., Cribbs, L.L., Byron, K.L., 2006. Pharmacological and electrophysiological characterization of store-operated currents and capacitative Ca^{2+} entry in vascular smooth muscle cells. *J. Pharmacol. Exp. Ther.* 317, 488–499.
- Catterall, W.A., 2000. Structure and regulation of voltage-gated Ca^{2+} channels. *Annu. Rev. Cell Dev. Biol.* 16, 521–555.
- Davenport, A.P., Battistini, B., 2002. Classification of endothelin receptors and antagonists in clinical development. *Clin. Sci.* 103 (48), 1S–3S.
- Dong, Y., Kunze, D.L., Vaca, L., Schilling, W.P., 1995. $\text{Ins}(1,4,5)\text{P}_3$ activates *Drosophila* cation channel Trp1 in recombinant baculovirus-infected Sf9 insect cells. *Am. J. Physiol.* 269, C1332–C1339.
- Facemire, C.S., Mohler, P.J., Arendshorst, W.J., 2004. Expression and relative abundance of short transient receptor potential channels in the rat renal microcirculation. *Am. J. Physiol. Renal Physiol.* 286, F546–F551.
- Flemming, R., Xu, S.Z., Beech, D.J., 2003. Pharmacological profile of store-operated channels in cerebral arteriolar smooth muscle cells. *Br. J. Pharmacol.* 139, 955–965.
- Guibert, C., Beech, D.J., 1999. Positive and negative coupling of the endothelin ET_A receptor to Ca^{2+} -permeable channels in rabbit cerebral cortex arterioles. *J. Physiol.* 514, 843–856.
- Helliwell, R.M., Large, W.A., 1997. Alpha 1-adrenoceptor activation of a non-selective cation current in rabbit portal vein by 1,2-diacyl-sn-glycerol. *J. Physiol.* 499, 417–428.
- Hill, A.J., Hinton, J.M., Cheng, H., Gao, Z., Bates, D.O., Hancox, J.C., Langton, P.D., James, A.F., 2006. A TRPC-like non-selective cation current activated by alpha(1)-adrenoceptors in rat mesenteric artery smooth muscle cells. *Cell Calcium* 40, 29–40.
- Hofmann, T., Obukhov, A.G., Schaefer, M., Harteneck, C., Gudermann, T., Schultz, G., 1999. Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. *Nature* 397, 259–263.
- Hofmann, T., Schaefer, M., Schultz, G., Gudermann, T., 2002. Subunit composition of mammalian transient receptor potential channels in living cells. *Proc. Natl. Acad. Sci. U S A* 99, 7461–7466.
- Inoue, R., Okada, T., Onoue, H., Hara, Y., Shimizu, S., Naitoh, S., Ito, Y., Mori, Y., 2001. The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca^{2+} -permeable cation channel. *Circ. Res.* 88, 325–332.
- Inoue, R., Hanano, T., Shi, J., Mori, Y., Ito, Y., 2003. Transient receptor potential protein as a novel non-voltage-gated Ca^{2+} entry channel involved in diverse pathophysiological functions. *J. Pharmacol. Sci.* 91, 271–276.
- Iwamuro, Y., Miwa, S., Zhang, X.F., Minowa, T., Enoki, T., Okamoto, Y., Hasegawa, H., Furutani, H., Okazawa, M., Ishikawa, M., Hashimoto, N., Masaki, T., 1999. Activation of three types of voltage-independent Ca^{2+} channel in A7r5 cells by endothelin-1 as revealed by a novel Ca^{2+} channel blocker LOE 908. *Br. J. Pharmacol.* 126, 1107–1114.
- Jung, S., Strotmann, R., Schultz, G., Plant, T.D., 2002. TRPC6 is a candidate channel involved in receptor-stimulated cation currents in A7r5 smooth muscle cells. *Am. J. Physiol., Cell Physiol.* 282, C347–C359.
- Jung, S., Muhle, A., Schaefer, M., Strotmann, R., Schultz, G., Plant, T.D., 2003. Lanthanides potentiate TRPC5 currents by an action at extracellular sites close to the pore mouth. *J. Biol. Chem.* 278, 3562–3571.
- Kawanabe, Y., Hashimoto, N., Masaki, T., 2002a. Characterization of Ca^{2+} channels involved in endothelin-1-induced contraction of rabbit basilar artery. *J. Cardiovasc. Pharmacol.* 40, 438–447.
- Kawanabe, Y., Okamoto, Y., Miwa, S., Hashimoto, N., Masaki, T., 2002b. Molecular mechanisms for the activation of voltage-independent Ca^{2+} channels by endothelin-1 in Chinese hamster ovary cells stably expressing human endothelin(A) receptors. *Mol. Pharmacol.* 62, 75–80.
- Krensek, P., Hamaide, M.C., Morel, N., Wibo, M., 2006. A simple method for rapid separation of endothelial and smooth muscle mRNA reveals Na^+/K^+ -ATPase alpha-subunit distribution in rat arteries. *J. Vasc. Res.* 43, 502–510.
- Kumar, B., Dreja, K., Shah, S.S., Cheong, A., Xu, S.Z., Sukumar, P., Naylor, J., Forte, A., Cipollaro, M., McHugh, D., Kingston, P.A., Heagerty, A.M., Munsch, C.M., Bergdahl, A., Hultgardh-Nilsson, A., Gomez, M.F., Porter, K.E., Hellstrand, P., Beech, D.J., 2006. Upregulated TRPC1 channel in vascular injury in vivo and its role in human neointimal hyperplasia. *Circ. Res.* 98, 557–563.
- Kunichika, N., Yu, Y., Remillard, C.V., Platoshyn, O., Zhang, S., Yuan, J.X., 2004. Overexpression of TRPC1 enhances pulmonary vasoconstriction induced by capacitative Ca^{2+} entry. *Am. J. Physiol., Lung Cell. Mol. Physiol.* 287, L962–L969.
- Lee, C.H., Rahimian, R., Szado, T., Sandhu, J., Poburko, D., Behra, T., Chan, L., van Breemen, C., 2002. Sequential opening of IP(3)-sensitive Ca^{2+} channels and SOC during alpha-adrenergic activation of rabbit vena cava. *Am. J. Physiol. Heart Circ. Physiol.* 282, H1768–H1777.
- Lievremont, J.P., Bird, G.S., Putney Jr., J.W., 2005. Mechanism of inhibition of TRPC cation channels by 2-aminoethoxydiphenylborane. *Mol. Pharmacol.* 68, 758–762.
- Lin, M.J., Leung, G.P., Zhang, W.M., Yang, X.R., Yip, K.P., Tse, C.M., Sham, J.S., 2004. Chronic hypoxia-induced upregulation of store-operated and receptor-operated Ca^{2+} channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension. *Circ. Res.* 95, 496–505.
- Lintschinger, B., Balzer-Geldsetzer, M., Baskaran, T., Graier, W.F., Romanin, C., Zhu, M.X., Groschner, K., 2000. Coassembly of Trp1 and Trp3 proteins generates diacylglycerol- and Ca^{2+} -sensitive cation channels. *J. Biol. Chem.* 275, 27799–27805.
- Liu, X., Bandyopadhyay, B.C., Singh, B.B., Groschner, K., Ambudkar, I.S., 2005. Molecular analysis of a store-operated and 2-acetyl-sn-glycerol-sensitive non-selective cation channel. Heteromeric assembly of TRPC1-TRPC3. *J. Biol. Chem.* 280, 21600–21606.

- Lockwich, T.P., Liu, X., Singh, B.B., Jadowiec, J., Weiland, S., Ambudkar, I.S., 2000. Assembly of Trp1 in a signaling complex associated with caveolin-scaffolding lipid raft domains. *J. Biol. Chem.* 275, 11934–11942.
- Ma, H.T., Patterson, R.L., van Rossum, D.B., Birnbaumer, L., Mikoshiba, K., Gill, D.L., 2000. Requirement of the inositol trisphosphate receptor for activation of store-operated Ca^{2+} channels. *Science* 287, 1647–1651.
- Ma, H.T., Venkatachalam, K., Li, H.S., Montell, C., Kurosaki, T., Patterson, R.L., Gill, D.L., 2001. Assessment of the role of the inositol 1,4,5-trisphosphate receptor in the activation of transient receptor potential channels and store-operated Ca^{2+} entry channels. *J. Biol. Chem.* 276, 18888–18896.
- Maruyama, T., Kanaji, T., Nakade, S., Kanno, T., Mikoshiba, K., 1997. 2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins (1,4,5) P_3 -induced Ca^{2+} release. *J. Biochem.* 122, 498–505.
- Maruyama, Y., Nakanishi, Y., Walsh, E.J., Wilson, D.P., Welsh, D.G., Cole, W.C., 2006. Heteromultimeric TRPC6-TRPC7 channels contribute to arginine vasopressin-induced cation current of A7r5 vascular smooth muscle cells. *Circ. Res.* 98, 1520–1527.
- McDaniel, S.S., Platoshyn, O., Wang, J., Yu, Y., Sweeney, M., Krick, S., Rubin, L.J., Yuan, J.X., 2001. Capacitative Ca^{2+} entry in agonist-induced pulmonary vasoconstriction. *Am. J. Physiol., Lung Cell. Mol. Physiol.* 280, L870–L880.
- McFadzean, I., Gibson, A., 2002. The developing relationship between receptor-operated and store-operated calcium channels in smooth muscle. *Br. J. Pharmacol.* 135, 1–13.
- Mehta, D., Ahmed, G.U., Paria, B.C., Holinstat, M., Voyno-Yasenetskaya, T., Tiruppathi, C., Minshall, R.D., Malik, A.B., 2003. RhoA interaction with inositol 1,4,5-trisphosphate receptor and transient receptor potential channel-1 regulates Ca^{2+} entry. Role in signaling increased endothelial permeability. *J. Biol. Chem.* 278, 33492–33500.
- Missiaen, L., Declercq, I., Droogmans, G., Plessers, L., De Smedt, H., Raeymaekers, L., Casteels, R., 1990. Agonist-dependent Ca^{2+} and Mn^{2+} entry dependent on state of filling of Ca^{2+} stores in aortic smooth muscle cells of the rat. *J. Physiol.* 427, 171–186.
- Miwa, S., Kawanabe, Y., Okamoto, Y., Masaki, T., 2005. Ca^{2+} entry channels involved in endothelin-1-induced contractions of vascular smooth muscle cells. *J. Smooth Muscle Res.* 41, 61–75.
- Moneer, Z., Taylor, C.W., 2002. Reciprocal regulation of capacitative and non-capacitative Ca^{2+} entry in A7r5 vascular smooth muscle cells: only the latter operates during receptor activation. *Biochem. J.* 362, 13–21.
- Moneer, Z., Pino, I., Taylor, E.J., Broad, L.M., Liu, Y., Tovey, S.C., Staali, L., Taylor, C.W., 2005. Different phospholipase-C-coupled receptors differentially regulate capacitative and non-capacitative Ca^{2+} entry in A7r5 cells. *Biochem. J.* 389, 821–829.
- Munaron, L., Antonietti, S., Distasi, C., Lovisolo, D., 1997. Arachidonic acid mediates calcium influx induced by basic fibroblast growth factor in Balb-c 3T3 fibroblasts. *Cell Calcium* 22, 179–188.
- Nilius, B., Droogmans, G., Wondereg, R., 2003. Transient receptor potential channels in endothelium: solving the calcium entry puzzle? *Endothelium* 10, 5–15.
- Oonuma, H., Nakajima, T., Nagata, T., Iwasawa, K., Wang, Y., Hazama, H., Morita, Y., Yamamoto, K., Nagai, R., Omata, M., 2000. Endothelin-1 is a potent activator of nonselective cation currents in human bronchial smooth muscle cells. *Am. J. Respir. Cell Mol. Biol.* 23, 213–221.
- Peppiatt, C.M., Collins, T.J., Mackenzie, L., Conway, S.J., Holmes, A.B., Bootman, M.D., Berridge, M.J., Seo, J.T., Roderick, H.L., 2003. 2-Aminoethoxydiphenyl borate (2-APB) antagonises inositol 1,4,5-trisphosphate-induced calcium release, inhibits calcium pumps and has a use-dependent and slowly reversible action on store-operated calcium entry channels. *Cell Calcium* 34, 97–108.
- Peppiatt-Wildman, C.M., Albert, A.P., Saleh, S.N., Large, W.A., 2007. Endothelin-1 activates a Ca^{2+} -permeable cation channel with TRPC3 and TRPC7 properties in rabbit coronary artery myocytes. *J. Physiol.* 580, 755–764.
- Poburko, D., Lhote, P., Szado, T., Behra, T., Rahimian, R., McManus, B., van Breemen, C., Ruegg, U.T., 2004. Basal calcium entry in vascular smooth muscle. *Eur. J. Pharmacol.* 505, 19–29.
- Putney Jr., J.W., 2004. The enigmatic TRPCs: multifunctional cation channels. *Trends Cell. Biol.* 14, 282–286.
- Putney Jr., J.W., Broad, L.M., Braun, F.J., Lievreumont, J.P., Bird, G.S., 2001. Mechanisms of capacitative calcium entry. *J. Cell. Sci.* 114, 2223–2229.
- Reading, S.A., Earley, S., Waldron, B.J., Welsh, D.G., Brayden, J.E., 2005. TRPC3 mediates pyrimidine receptor-induced depolarization of cerebral arteries. *Am. J. Physiol., Heart Circ. Physiol.* 288, H2055–H2061.
- Rosado, J.A., Sage, S.O., 2000. Coupling between inositol 1,4,5-trisphosphate receptors and human transient receptor potential channel 1 when intracellular Ca^{2+} stores are depleted. *Biochem. J.* 350 (3), 631–635.
- Saleh, S.N., Albert, A.P., Peppiatt, C.M., Large, W.A., 2006. Angiotensin II activates two cation conductances with distinct TRPC1 and TRPC6 channel properties in rabbit mesenteric artery myocytes. *J. Physiol.* 577, 479–495.
- Shuttleworth, T.J., Thompson, J.L., Mignen, O., 2004. ARC channels: a novel pathway for receptor-activated calcium entry. *Physiology* 19, 355–361.
- Smani, T., Zakharov, S.I., Csutora, P., Leno, E., Trepakova, E.S., Bolotina, V.M., 2004. A novel mechanism for the store-operated calcium influx pathway. *Nat. Cell Biol.* 6, 113–120.
- Soulsby, M.D., Wojcikiewicz, R.J., 2002. 2-Aminoethoxydiphenyl borate inhibits inositol 1,4,5-trisphosphate receptor function, ubiquitination and downregulation, but acts with variable characteristics in different cell types. *Cell Calcium* 32, 175–181.
- Strubing, C., Krapivinsky, G., Krapivinsky, L., Clapham, D.E., 2001. TRPC1 and TRPC5 form a novel cation channel in mammalian brain. *Neuron* 29, 645–655.
- Strubing, C., Krapivinsky, G., Krapivinsky, L., Clapham, D.E., 2003. Formation of novel TRPC channels by complex subunit interactions in embryonic brain. *J. Biol. Chem.* 278, 39014–39019.
- Sweeney, M., Yu, Y., Platoshyn, O., Zhang, S., McDaniel, S.S., Yuan, J.X., 2002. Inhibition of endogenous TRP1 decreases capacitative Ca^{2+} entry and attenuates pulmonary artery smooth muscle cell proliferation. *Am. J. Physiol., Lung Cell. Mol. Physiol.* 283, L144–L155.
- Sydorenko, V., Shuba, Y., Thebault, S., Roudbaraki, M., Lepage, G., Prevarskaya, N., Skryma, R., 2003. Receptor-coupled, DAG-gated Ca^{2+} -permeable cationic channels in LNCaP human prostate cancer epithelial cells. *J. Physiol.* 548, 823–836.
- Tiruppathi, C., Minshall, R.D., Paria, B.C., Vogel, S.M., Malik, A.B., 2002. Role of Ca^{2+} signaling in the regulation of endothelial permeability. *Vascul. Pharmacol.* 39, 173–185.
- Tousova, K., Vyklicky, L., Susankova, K., Benedikt, J., Vlachova, V., 2005. Gadolinium activates and sensitizes the vanilloid receptor TRPV1 through the external protonation sites. *Mol. Cell. Neurosci.* 30, 207–217.
- Trebak, M., St John Bird, G., McKay, R.R., Putney Jr., J.W., 2002. Comparison of human TRPC3 channels in receptor-activated and store-operated modes. Differential sensitivity to channel blockers suggests fundamental differences in channel composition. *J. Biol. Chem.* 277, 21617–21623.
- Vazquez, G., Wedel, B.J., Trebak, M., St John Bird, G., Putney Jr., J.W., 2003. Expression level of the canonical transient receptor potential 3 (TRPC3) channel determines its mechanism of activation. *J. Biol. Chem.* 278, 21649–21654.
- Wang, J., Shimoda, L.A., Sylvester, J.T., 2004. Capacitative calcium entry and TRPC channel proteins are expressed in rat distal pulmonary arterial smooth muscle. *Am. J. Physiol., Lung Cell. Mol. Physiol.* 286, L848–L858.
- Wilson, S.M., Mason, H.S., Smith, G.D., Nicholson, N., Johnston, L., Janiak, R., Hume, J.R., 2002. Comparative capacitative calcium entry mechanisms in canine pulmonary and renal arterial smooth muscle cells. *J. Physiol.* 543, 917–931.
- Xu, S.Z., Beech, D.J., 2001. TrpC1 is a membrane-spanning subunit of store-operated Ca^{2+} channels in native vascular smooth muscle cells. *Circ. Res.* 88, 84–87.
- Yamamoto, H., Kanaide, H., Nakamura, M., 1990. Heparin specifically inhibits the inositol 1,4,5-trisphosphate-induced Ca^{2+} release from skinned rat aortic smooth muscle cells in primary culture. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 341, 273–278.
- Yu, Y., Sweeney, M., Zhang, S., Platoshyn, O., Landsberg, J., Rothman, A., Yuan, J.X., 2003. PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. *Am. J. Physiol., Cell Physiol.* 284, C316–C330.
- Yuan, J.P., Kiselyov, K., Shin, D.M., Chen, J., Shcheynikov, N., Kang, S.H., Dehoff, M.H., Schwarz, M.K., Seeburg, P.H., Muallem, S., Worley, P.F., 2003. Homer binds TRPC family channels and is required for gating of TRPC1 by IP_3 receptors. *Cell* 114, 777–789.

- Zagranichnaya, T.K., Wu, X., Villereal, M.L., 2005. Endogenous TRPC1, TRPC3, and TRPC7 proteins combine to form native store-operated channels in HEK-293 cells. *J. Biol. Chem.* 280, 29559–29569.
- Zhang, X.F., Iwamuro, Y., Enoki, T., Okazawa, M., Lee, K., Komuro, T., Minowa, T., Okamoto, Y., Hasegawa, H., Furutani, H., Miwa, S., Masaki, T., 1999. Pharmacological characterization of Ca^{2+} entry channels in endothelin-1-induced contraction of rat aorta using LOE 908 and SK&F 96365. *Br. J. Pharmacol.* 127, 1388–1398.
- Zitt, C., Zobel, A., Obukhov, A.G., Harteneck, C., Kalkbrenner, F., Luckhoff, A., Schultz, G., 1996. Cloning and functional expression of a human Ca^{2+} -permeable cation channel activated by calcium store depletion. *Neuron* 16, 1189–1196.